Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells

Authors: Tian-Song Xia, Jing-Ping Shi, Qiang Ding, Xiao-An Liu, Yi Zhao, Yue-Xian Liu, Jian-Guo Xia, Shui Wang, Yong-Bin Ding

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

Spleen tyrosine kinase (Syk) is reported to be involved in the suppression of proliferation and invasion of breast cancer. Methylation-mediated Syk gene silencing is found in a subset of breast cancer. In this study, we used a DNA methyltransferase inhibitor, 5-aza-2-deoxycytidine (AZA), to restore Syk expression of breast cancer cells. Surprisingly, we found that AZA treatment could reestablish the expression of Syk, but not affect the proliferation of breast cancer cells. Moreover, tumor formation in situ by MDA-MB-435s treated with (+) or without (−) AZA in a nude mice MFP (Mammary fat pad) model did not show significant difference, too. Interestingly, pulmonary metastasis was still significantly suppressed in MDA-MB-435s(+) group (1/9 vs. 7/9). Our findings suggested Syk may be more correlated to metastasis rather than proliferation. This study implied a potential use of Syk methylation as a valuable biomarker to detect high metastatic potential cancerous lesions and the prospect of AZA to join the arsenal of drug candidates to be developed as a new reagent for management of advanced breast cancer.
Literature
1.
go back to reference Hedley BD, Allan AL, Chambers AF. Tumor dormancy and the role of metastasis suppressor genes in regulating ectopic growth. Future Oncol. 2006;2(5):627–41.PubMedCrossRef Hedley BD, Allan AL, Chambers AF. Tumor dormancy and the role of metastasis suppressor genes in regulating ectopic growth. Future Oncol. 2006;2(5):627–41.PubMedCrossRef
2.
go back to reference Harris L, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.PubMedCrossRef Harris L, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.PubMedCrossRef
3.
go back to reference Katz E, et al. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer. 2010;103(3):401–10.PubMedCrossRef Katz E, et al. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer. 2010;103(3):401–10.PubMedCrossRef
4.
go back to reference Duenas-Gonzalez A, et al. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer. 2005;4:38.PubMedCrossRef Duenas-Gonzalez A, et al. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer. 2005;4:38.PubMedCrossRef
5.
go back to reference Mani S, Herceg Z. DNA demethylating agents and epigenetic therapy of cancer. Adv Genet. 2010;70:327–40.PubMedCrossRef Mani S, Herceg Z. DNA demethylating agents and epigenetic therapy of cancer. Adv Genet. 2010;70:327–40.PubMedCrossRef
6.
go back to reference Chu DH, Morita CT, Weiss A. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol Rev. 1998;165:167–80.PubMedCrossRef Chu DH, Morita CT, Weiss A. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol Rev. 1998;165:167–80.PubMedCrossRef
7.
go back to reference Kurosaki T. Molecular mechanisms in B cell antigen receptor signaling. Curr Opin Immunol. 1997;9(3):309–18.PubMedCrossRef Kurosaki T. Molecular mechanisms in B cell antigen receptor signaling. Curr Opin Immunol. 1997;9(3):309–18.PubMedCrossRef
8.
go back to reference Nakashima H, et al. Clinical significance of nuclear expression of spleen tyrosine kinase (Syk) in gastric cancer. Cancer Lett. 2006;236(1):89–94.PubMedCrossRef Nakashima H, et al. Clinical significance of nuclear expression of spleen tyrosine kinase (Syk) in gastric cancer. Cancer Lett. 2006;236(1):89–94.PubMedCrossRef
9.
go back to reference Gatalica Z, Bing Z. Syk tyrosine kinase expression during multistep mammary carcinogenesis. Croat Med J. 2005;46(3):372–6.PubMed Gatalica Z, Bing Z. Syk tyrosine kinase expression during multistep mammary carcinogenesis. Croat Med J. 2005;46(3):372–6.PubMed
10.
go back to reference Coopman PJ, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature. 2000;406(6797):742–7.PubMedCrossRef Coopman PJ, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature. 2000;406(6797):742–7.PubMedCrossRef
11.
go back to reference Yuan Y, Mendez R, Sahin A, Dai JL. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 2001;61(14):5558–61.PubMed Yuan Y, Mendez R, Sahin A, Dai JL. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 2001;61(14):5558–61.PubMed
12.
go back to reference Wang L, et al. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 2003;63(15):4724–30.PubMed Wang L, et al. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 2003;63(15):4724–30.PubMed
13.
go back to reference Carter WB, Hoying JB, Boswell C, Williams SK. HER2/neu over-expression induces endothelial cell retraction. Int J Cancer. 2001;91(3):295–9.PubMedCrossRef Carter WB, Hoying JB, Boswell C, Williams SK. HER2/neu over-expression induces endothelial cell retraction. Int J Cancer. 2001;91(3):295–9.PubMedCrossRef
14.
go back to reference Gururajan M, et al. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol. 2007;178(1):111–21.PubMed Gururajan M, et al. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol. 2007;178(1):111–21.PubMed
15.
go back to reference Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem. 2001;130(2):177–86.PubMedCrossRef Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem. 2001;130(2):177–86.PubMedCrossRef
16.
go back to reference Li J, Sidell N. Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase. Int J Cancer. 2005;117(1):14–20.PubMedCrossRef Li J, Sidell N. Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase. Int J Cancer. 2005;117(1):14–20.PubMedCrossRef
17.
go back to reference Mahabeleshwar GH, Kundu GC. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3’-kinase activity in breast cancer cells. J Biol Chem. 2003;278(8):6209–21.PubMedCrossRef Mahabeleshwar GH, Kundu GC. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3’-kinase activity in breast cancer cells. J Biol Chem. 2003;278(8):6209–21.PubMedCrossRef
18.
go back to reference Moroni M, et al. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res. 2004;64(20):7346–54.PubMedCrossRef Moroni M, et al. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res. 2004;64(20):7346–54.PubMedCrossRef
19.
go back to reference Yuan Y, Liu H, Sahin A, Dai JL. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer. 2005;113(4):654–9.PubMedCrossRef Yuan Y, Liu H, Sahin A, Dai JL. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer. 2005;113(4):654–9.PubMedCrossRef
20.
go back to reference Crespo M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764–75.PubMedCrossRef Crespo M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764–75.PubMedCrossRef
21.
go back to reference Inatome R, Yanagi S, Takano T, Yamamura H. A critical role for Syk in endothelial cell proliferation and migration. Biochem Biophys Res Commun. 2001;286(1):195–9.PubMedCrossRef Inatome R, Yanagi S, Takano T, Yamamura H. A critical role for Syk in endothelial cell proliferation and migration. Biochem Biophys Res Commun. 2001;286(1):195–9.PubMedCrossRef
22.
go back to reference Larive RM, et al. Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion. Oncogene. 2009;28(24):2337–47.PubMedCrossRef Larive RM, et al. Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion. Oncogene. 2009;28(24):2337–47.PubMedCrossRef
23.
go back to reference Zhang X, Shrikhande U, Alicie BM, Zhou Q, Geahlen RL. Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res. 2009;7(5):634–44.PubMedCrossRef Zhang X, Shrikhande U, Alicie BM, Zhou Q, Geahlen RL. Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res. 2009;7(5):634–44.PubMedCrossRef
24.
go back to reference Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821–6.PubMedCrossRef Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821–6.PubMedCrossRef
25.
go back to reference Wang L, Devarajan E, He J, Reddy SP, Dai JL. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res. 2005;65(22):10289–97.PubMedCrossRef Wang L, Devarajan E, He J, Reddy SP, Dai JL. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res. 2005;65(22):10289–97.PubMedCrossRef
26.
go back to reference Toyama T, et al. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett. 2003;189(1):97–102.PubMedCrossRef Toyama T, et al. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett. 2003;189(1):97–102.PubMedCrossRef
27.
go back to reference Sung YM, et al. Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLoS One. 2009;4(10):e7445.PubMedCrossRef Sung YM, et al. Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLoS One. 2009;4(10):e7445.PubMedCrossRef
28.
go back to reference Schymeinsky J, Then C, Walzog B. The non-receptor tyrosine kinase Syk regulates lamellipodium formation and site-directed migration of human leukocytes. J Cell Physiol. 2005;204(2):614–22.PubMedCrossRef Schymeinsky J, Then C, Walzog B. The non-receptor tyrosine kinase Syk regulates lamellipodium formation and site-directed migration of human leukocytes. J Cell Physiol. 2005;204(2):614–22.PubMedCrossRef
29.
go back to reference Zyss D, et al. The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression. Cancer Res. 2005;65(23):10872–80.PubMedCrossRef Zyss D, et al. The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression. Cancer Res. 2005;65(23):10872–80.PubMedCrossRef
30.
go back to reference Hoeller C, et al. The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol. 2005;124(6):1293–9.PubMedCrossRef Hoeller C, et al. The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol. 2005;124(6):1293–9.PubMedCrossRef
31.
go back to reference Dejmek J, et al. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res. 2005;11((2 Pt 1)):520–8.PubMed Dejmek J, et al. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res. 2005;11((2 Pt 1)):520–8.PubMed
32.
go back to reference Kienle DL, et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol. 2005;23(16):3780–92.PubMedCrossRef Kienle DL, et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol. 2005;23(16):3780–92.PubMedCrossRef
33.
go back to reference Marafioti T, et al. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood. 2004;103(1):188–93.PubMedCrossRef Marafioti T, et al. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood. 2004;103(1):188–93.PubMedCrossRef
34.
go back to reference Thompson MA, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol. 2005;36(5):494–504.PubMedCrossRef Thompson MA, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol. 2005;36(5):494–504.PubMedCrossRef
35.
go back to reference Dong G, et al. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. Cancer Res. 2001;61(12):4797–808.PubMed Dong G, et al. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. Cancer Res. 2001;61(12):4797–808.PubMed
36.
go back to reference Al-Sahaf O, Wang JH, Browne TJ, Cotter TG, Redmond HP. Surgical injury enhances the expression of genes that mediate breast cancer metastasis to the lung. Ann Surg. 2010;252(6):1037–43.PubMedCrossRef Al-Sahaf O, Wang JH, Browne TJ, Cotter TG, Redmond HP. Surgical injury enhances the expression of genes that mediate breast cancer metastasis to the lung. Ann Surg. 2010;252(6):1037–43.PubMedCrossRef
Metadata
Title
Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells
Authors
Tian-Song Xia
Jing-Ping Shi
Qiang Ding
Xiao-An Liu
Yi Zhao
Yue-Xian Liu
Jian-Guo Xia
Shui Wang
Yong-Bin Ding
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9865-4

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.